Format

Send to

Choose Destination
Hum Mol Genet. 2018 May 1;27(R1):R72-R78. doi: 10.1093/hmg/ddy116.

Pharmacogenomics and big genomic data: from lab to clinic and back again.

Author information

1
Biomedical Informatics Training Program, Stanford University, Stanford, CA 94305, USA.
2
Department of Genetics, Stanford University, Stanford, CA 94305, USA.
3
Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA.
4
Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.

Abstract

The field of pharmacogenomics is an area of great potential for near-term human health impacts from the big genomic data revolution. Pharmacogenomics research momentum is building with numerous hypotheses currently being investigated through the integration of molecular profiles of different cell lines and large genomic data sets containing information on cellular and human responses to therapies. Additionally, the results of previous pharmacogenetic research efforts have been formulated into clinical guidelines that are beginning to impact how healthcare is conducted on the level of the individual patient. This trend will only continue with the recent release of new datasets containing linked genotype and electronic medical record data. This review discusses key resources available for pharmacogenomics and pharmacogenetics research and highlights recent work within the field.

PMID:
29635477
PMCID:
PMC5946941
DOI:
10.1093/hmg/ddy116
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center